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A B S T R A C T
Dysgerminomas are aggressive germ cell tumors that typically have a favorable prognosis, especially in patients
diagnosed with early stage disease. We recount the history of a 23-year-old woman who was treated for a stage
IA ovarian dysgerminoma in November 2017. Postoperatively, the patient was noncompliant insofar as ob-
taining routine lab evaluations; ten months later, she was diagnosed with a cranial metastasis that extended into
the meninges. The patient subsequently underwent a posterior fossa craniotomy and adjuvant etoposide, bleo-
mycin and cisplatin chemotherapy to which she initially responded; however, during cycle 4, she developed
pancytopenia whereupon the chemotherapy was summarily discontinued. Thereafter, the patient was surveilled
and currently, she remains in clinical remission. Early stage ovarian dysgerminoma, albeit rarely, has the ca-
pacity to metastasize to the cranium or brain, further underscoring the significance of employing active follow-
up with these patients.
1. Introduction
Dysgerminomas comprise approximately 2% of all ovarian malig-
nancies and nearly 33% of malignant ovarian germ cell neoplasms
(Zogbi et al., 2018). They frequently manifest themselves in young
adults or adolescents and have a proclivity for rapid growth (Mangili
et al., 2011). When they manifest themselves, ovarian dysgerminomas
routinely coincide with abdominal distention, pain and menstrual ab-
normalities (Zogbi et al., 2018).
Dysgerminoma, the ovarian counterpart of testicular seminoma, is
composed of undifferentiated germ and large vesicular cells with in-
terspersed, scant fibrous stroma (Zaloudek et al., 1981). They are
characteristically unilateral and grossly, resemble a tan-colored, lobu-
lated, firm mass (Gordon et al., 1981). On ultrasound, dysgerminomas
are depicted as a highly vascularized, large, solid, lobulated adnexal
mass with irregular, internal echogenicity (Guerriero et al., 2011).
Despite their malignant propensity, stage I dysgerminoma patient 5-
year survival rates are approximately 90% (Gallion et al., 1988).
Conversely, relapse rates for stage IA disease are nearly 20%, (Patterson
et al., 2008) wherein the disease is often identified within the con-
tralateral ovary, pelvis and abdomen (Mangili et al., 2011; A L Husaini
et al., 2012).
When dysgerminomas metastasize, the disease is typically en-
countered in the para-aortic or supraclavicular lymph nodes (Mangili
et al., 2011; A L Husaini et al., 2012), whereas the breast is very un-
common (Kattan et al., 1992) and neurologic involvement is exceed-
ingly rare (Afridi et al., 1976; Jolles et al., 1989). In the current study,
we recount the extraordinary occurrence of an ovarian dysgerminoma
patient who developed metastatic disease that infiltrated her cranium
and dura mater.
2. Case report
A 23-year-old, nulligravid woman with a history of polycystic ovary
syndrome, migraines and bipolar disorder originally presented to an
outside medical facility in November 2017 with pelvic pain and a 11 cm
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pelvic mass depicted on ultrasound. She had a CA-125 of 55.7 U/mL, a
negative beta human chorionic gonadotropin (HCG) test, a carci-
noembryonic antigen (CEA) of 0.8 ng/mL and alpha-fetoprotein
(AFP)< 0.7 ng/mL; her lactate dehydrogenase (LDH) was not mea-
sured.
The patient underwent a diagnostic laparoscopy, exploratory la-
parotomy and right salpingo-oophorectomy for a presumed stage IA
dysgerminoma. Postoperatively, a CT scan of the chest, abdomen and
pelvis in November 2017 precluded tumor deposits, ascites or adeno-
pathy; notably, the resected right ovary contained a 5 cm cyst. Final
pathology revealed a stage IA ovarian dysgerminoma. The patient was
subsequently referred to our gynecologic oncology service for surveil-
lance.
In January 2018, the patient's LDH was 361 U/L, her CA-125 was
9 U/mL and a CT scan of the abdomen and pelvis was negative for re-
current disease. She was prescribed bi-monthly evaluations although
the patient was non-compliant and only returned in May 2018; never-
theless, she was asymptomatic and her LDH and CA-125 levels were
147 U/L and 3 U/mL, respectively.
In July 2018, the patient complained of neck swelling, malaise,
anorexia, abdominal bloating, diarrhea and migratory pain; her CA-125
was 133 U/mL but she neglected to have her LDH levels measured.
Additionally, the patient developed a persistent cough and scalp cel-
lulitis for which she was prescribed Bactrim at an urgent care facility.
In September 2018, the patient was admitted to the emergency
room for a painful, enlarging right parietal scalp mass; her LDH
was>4000 U/L. Preoperative cranial CT imaging revealed a
6.4 cm×5.2 cm right posterior lesion infiltrating the right parietal
bone with superficial extension into the skull and intra-axial involve-
ment (Fig. 1). The patient subsequently underwent a right parietal
craniotomy with resection of the skull mass and attendant dura mater
(Fig. 2); a postoperative PET scan was negative for residual disease. The
frozen section was consistent with her primary ovarian dysgerminoma
(Fig. 3a & b).
In October 2018, the patient's LDH was 271 U/L and her CA-125
was 19 U/mL. She commenced with four cycles of intravenous bleo-
mycin (15 units/wk. on days 1, 8, and 15), intravenous etoposide 120
(mg/m2), and intravenous cisplatin (40mg/m2 on days 1–5); her
November 2018 lab values remained stable. Inauspiciously, at cycle 3,
the patient's LDH was elevated at 380 U/L but during cycle four, her
LDH (254 U/L) and CA-125 (15 U/mL) levels decreased; unfortunately,
the patient thereupon developed pancytopenia whereupon the che-
motherapy was discontinued. Currently, she is doing well and under-
going routine surveillance by her gynecologic oncologist.
3. Conclusions
Dysgerminomas are aggressive lesions that predominantly infiltrate
via direct extension, the lymphatic system or in advanced cases, he-
matogenously (Mangili et al., 2011; Patterson et al., 2008). Char-
acteristically, they respond favorably to treatment and are associated
with an overall 5-year survival rate approximating 90% (Mangili et al.,
2011; Gallion et al., 1988). Similarly, relapse rates for dysgerminoma
patients with early stage disease are approximately 20% and often at-
tributed to postoperative residual disease (Patterson et al., 2008). In
one dysgerminoma study, the 5-year survival rate was 61% for the
optimally cytoreduced group (≤1 cm), compared with 14% in the sub-
optimal surgery cohort (Li and Xiaohua, 2016).
We describe herein, a patient who underwent surgical treatment for
a stage IA ovarian dysgerminoma. Postoperatively, she was relatively
noncompliant and did not adhere to her prescribed surveillance; within
ten months of the patient's initial diagnosis, she developed an ovarian
dysgerminoma that was metastatic to the cranium and meninges.
There have been reported studies documenting ovarian dysgermi-
nomas that metastasize to the lymph nodes (A L Husaini et al., 2012)
and albeit rarely, the breast (Kattan et al., 1992). However, the iden-
tification of an ovarian dysgerminoma metastatic to the brain (Afridi
et al., 1976; Jolles et al., 1989), let alone the cranium, is exceptionally
uncommon. Jolles et al. reported on an advanced ovarian dysgermi-
noma patient who developed carcinomatous meningitis while under-
going vinblastine, cisplatin and bleomycin chemotherapy (Jolles et al.,
1989). In another study, a 21-year-old woman was treated with a total
abdominal hysterectomy, bilateral salpingo-oophorectomy and pelvic
radiotherapy (30 Gy) for a stage IB, 25 cm ovarian dysgerminoma
(Afridi et al., 1976). However, she recurred in the pelvic lymph nodes
within 6months and afterward developed pulmonary metastases; in
both instances, she was treated with radiotherapy. Five months later,
the patient complained of a headache and weakness, which was as-
cribed to a right parietal lobe metastasis originating from her primary
disease.
Despite the similarities, our patient had a stage IA dysgerminoma,
whereas the aforesaid subjects were afflicted with advanced stage dis-
ease. However, we recognize that our patient was initially not surgi-
cally staged, which might have eventuated upstaging; accordingly, the
potential inclusion of adjuvant chemotherapy may have attenuated the
patient's risk for recurrence. Moreover, the two case studies reported on
disease involving either the brain parenchyma or extra-parenchymal
tissue (Afridi et al., 1976; Jolles et al., 1989); in contradistinction, our
patient was afflicted with metastatic cancer that infiltrated the cranium
and meninges. While there have been reports depicting cranial
Fig. 1. Axial post contrast MRI demonstrates the aggressive enhancing mass
(arrow) involving the right parietal bone with both extra- and intracranial in-
volvement.
Fig. 2. Gross photograph of the metastatic dysgerminoma mass.
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metastases originating from a testicular germ cell tumor (Uygun et al.,
2006), we were only able to identify one gynecologic case study in-
volving a mature ovarian teratoma patient whose disease metastasized
to the cranial vault (Tokuda et al., 1993).
When managing a dysgerminoma, surgery is not only beneficial but
the sine qua non for diagnosis and staging (Mangili et al., 2011). Young
patients diagnosed with a dysgerminoma who desire fertility and are at
risk for recurrence should be counseled regarding the potential for
oocyte/embryo cryopreservation before and/or after the completion of
chemotherapy. Bleomycin, etoposide, and cisplatin is an established
regimen for advanced disease and an independent prognostic indicator
for improved patient outcomes (Mangili et al., 2011). Regrettably,
persistent disease may be ultimately discerned in the brain due to the
blood-brain barrier's ability to preclude chemotherapy delivery (Weidle
et al., 2015); in select cases with CNS disease involvement, radiation
therapy may also confer a limited benefit (Fosså et al., 1999). Vigilant
surveillance of patients, comprising frequent clinic evaluations, serial
tumor marker (e.g., LDH, beta-hCG, CA-125) and routine imaging
(Zogbi et al., 2018; Gordon et al., 1981), is strongly recommended.
Declaration of Competing Interests
All authors deny any conflict of interest associated with this
manuscript.
Author contributions
TB contributed significantly to the study's initiation, development
and manuscript revision.
BG substantially contributed to the study's development and
manuscript revision.
HM conducted the review of the patient's pathologic diagnosis and
treatment history and also substantially contributed to the study's de-
velopment and manuscript revision.
JD was instrumental in reviewing the patient's charge and con-
ducting the radiologic evaluation.
RB reviewed the patient's chart, analyzed the chemotherapy treat-
ment lines and corresponding outcomes, and significantly assisted with
the manuscript development and revision.
VR commented on the surgical evaluation, reviewed the patient's
postop data and significantly assisted with the manuscript development
and revision.
References
A L Husaini, H., Soudy, H., El Din Darwish, A., Ahmed, M., Eltigani, A., A L Mubarak, M.,
et al., 2012. Pure dysgerminoma of the ovary: a single institutional experience of 65
patients. Med. Oncol. 29, 2944–2948.
Afridi, M.A., Vongtama, V., Tsukada, Y., Piver, M.S., 1976. Dysgerminoma of the ovary:
radiation therapy for recurrence and metastases. Am. J. Obstet. Gynecol. 126,
190–194.
Fosså, S.D., Bokemeyer, C., Gerl, A., Culine, S., Jones, W.G., Mead, G.M., et al., 1999.
Treatment outcome of patients with brain metastases from malignant germ cell tu-
mors. Cancer 85, 988–997.
Gallion, H.H., van Nagell Jr., J.R., Donaldson, E.S., Powell, D.E., 1988. Ovarian dysger-
minoma: report of seven cases and review of the literature. Am. J. Obstet. Gynecol.
158, 591–595.
Gordon, A., Lipton, D., Woodruff, J.D., 1981. Dysgerminoma: a review of 158 cases from
the Emil Novak Ovarian Tumor Registry. Obstet. Gynecol. 58, 497–504.
Guerriero, S., Testa, A.C., Timmerman, D., Van Holsbeke, C., Ajossa, S., Fischerova, D.,
et al., 2011. Imaging of gynecological disease (6): clinical and ultrasound char-
acteristics of ovarian dysgerminoma. Ultrasound Obstet. Gynecol. 37, 596–602.
Jolles, C.J., Karayianis, S., Smotkin, D., DeLia, J.E., 1989. Advanced ovarian dysgermi-
noma with cure of tumor persistent in meninges. Gynecol. Oncol. 33, 389–391.
Kattan, J., Droz, J.P., Charpentier, P., Michel, G., Lhommé, C., Boutan-Laroze, A., Prade,
M., 1992. Ovarian dysgerminoma metastatic to the breast. Gynecol. Oncol. 46,
104–106.
Li, J., Xiaohua, W., 2016. Current strategy for the treatment of ovarian germ cell tumors:
role of extensive surgery. Curr. Treat. Options in Oncol. 17, 44.
Mangili, G., Sigismondi, C., Lorusso, D., Cormio, G., Scollo, P., Viganò, R., et al., 2011. Is
surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The
MITO group retrospective experience. Gynecol. Oncol. 121, 280–284.
Patterson, D.M., Murugaesu, N., Holden, L., Seckl, M.J., Rustin, G.J., 2008. A review of
the close surveillance policy for stage I female germ cell tumors of the ovary and
other sites. Int. J. Gynecol. Cancer 18, 43–50.
Tokuda, Y., Hatayama, T., Sakoda, K., 1993. Metastasis of malignant struma ovarii to the
cranial vault during pregnancy. Neurosurgery 33, 515–518.
Uygun, K., Karagol, H., Kocak, Z., Cicin, I., Yalcin, O., Caloglu, M., et al., 2006. Isolated
bone metastasis in testicular germ cell tumors: a case report and review of the lit-
erature. Onkologie 29, 93–95.
Weidle, U.H., Niewöhner, J., Tiefenthaler, G., 2015. The blood-brain barrier challenge for
the treatment of brain cancer, secondary brain metastases, and neurological diseases.
Cancer Genomics Proteomics 12, 167–177.
Zaloudek, C.J., Tavassoli, F.A., Norris, H.J., 1981. Dysgerminoma with syncytiotropho-
blastic giant cells. A histologically and clinically distinctive subtype of dysgermi-
noma. Am. J. Surg. Pathol. 5, 361–367.
Zogbi, L., Gonçalves, C.V., Tejada, V.F., Martins, D., Karam, F., Machado Dos Santos, S.,
et al., 2018. Treatment of bilateral ovarian dysgerminoma with 11-year follow-up: A
case report. Ann. Med. Surg. 33, 50–52.
Fig. 3. a. Dysgerminoma in the right ovary. b. Dysgerminoma involving the skull bone, with the morphology identical to that of the right ovarian tumor.
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